Skip to main content

Day: February 26, 2024

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed.” ISS states in its Ceapro FOR recommendation that “The arrangement is the result of arm’s length negotiations between the parties and carries sound strategic logic.” Aeterna Zentaris and Ceapro securityholders are encouraged to vote well in advance of the proxy voting deadline of 11:00 a.m. (Eastern time) on March 8, 2024 To obtain current information about voting your Aeterna Zentaris Common Shares and the merger of equals transaction, please visit www.AEZSmerger.com. Need help voting? Aeterna Zentaris shareholders please contact Kingsdale Advisors at 1-866-581-1513 (North America...

Continue reading

Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published

ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT26 FEBRUARY 2024 at 14.30 EET         Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published Orion Group’s Financial Statement documents for 2023 have been published. The documents are available in Finnish and English on the Company’s website at http://www.orion.fi/en and are attached to this release. The Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements as xHTML file. The primary statements and notes to the Consolidated financial statements have been labelled with XBRL tags. Authorised Public Accountants KPMG Oy Ab has provided an independent auditor’s reasonable assurance report on Orion’s ESEF Financial Statements in accordance...

Continue reading

Wearable Devices to Showcase Its Neural Gesture Control Technology at MWC Barcelona 2024

The Company will demonstrate its Mudra Developer Kit for B2B partners as well as the Mudra Band for Apple Watch users YOKNEAM ILLIT, ISRAEL, Feb. 26, 2024 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (AI)-powered touchless sensing wearables, today announced its participation at MWC Barcelona 2024, the world’s most influential exhibition for the connectivity and security ecosystem, where they will demonstrate neural gesture input technology targeting the B2B and B2C markets. The Company’s booth will be located at Hall 5 – 5E61 from Monday, February 26 to Thursday, February 29, 2024. At MWC, Wearable Devices will demonstrate its recently launched Mudra Development Kit (“MDK”) for B2B partners. Leveraging innovative...

Continue reading

Gilat Presents Fourth Quarter and Full Year 2023 Results

Q4 Revenue of $75.6 million, GAAP Operating Income of $2.9 million and Adjusted EBITDA of $9.4 million 2023 Revenue of $266.1 million, up 11% year over year, GAAP Operating Income of $28.1 million and Adjusted EBITDA of $36.4 million, up 44% YoY PETAH TIKVA, Israel, Feb. 26, 2024 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its unaudited results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial HighlightsRevenue of $75.6 million, up 4% compared with $72.6 million in Q4 2022; GAAP operating income of $2.9 million, compared with $6.1 million in Q4 2022; Non-GAAP operating income of $6.1 million, compared with $7.1 million in Q4 2022; GAAP net income of $3.4 million,...

Continue reading

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

– Phase 3 CSU studies expected to initiate in summer 2024 –– Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 –– Enrollment nearing completion in Phase 2 CIndU study; Data expected 2H 2024 –– Phase 2 PN study expected to start in early 2024; Positive Phase 1 PN data reported in oral presentation at WCI 2023 – HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update. “In 2023, Celldex made transformational progress across the barzolvolimab development program, reporting multiple positive data sets across mast cell mediated diseases where patients...

Continue reading

Freshpet, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Full Year 2023 Net Sales and Adjusted EBITDA Exceed Company GuidanceSixth Consecutive Year of >25% Net Sales GrowthProvides Full Year 2024 Outlook SECAUCUS, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Compared to Prior Year PeriodNet sales of $215.4 million, an increase of 29.9% Net income of $15.3 million, compared to net loss of $2.9 million Adjusted EBITDA of $31.3 million, compared to $18.8 million 1   2023 Financial Highlights Compared to Prior YearNet sales of $766.9 million, an increase of 28.8% Net loss of $33.6 million compared to net loss of $59.5 million Adjusted EBITDA of $66.6 million compared to $20.1 million 1“Our strong...

Continue reading

Waldencast Receives Positive Nasdaq Listing Determination

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) — Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that by decision dated February 22, 2024, a Nasdaq Hearings Panel (the “Panel”) granted Waldencast’s request for continued listing on The Nasdaq Stock Market LLC (“Nasdaq”), subject to Waldencast filing the interim financial statements for the six-month period ended June 30, 2023 with the Securities and Exchange Commission by April 1, 2024, and Waldencast’s continued compliance with all other applicable criteria for continued listing on Nasdaq. Waldencast is diligently working to evidence compliance with the terms of the Panel’s decision as soon as practicable and in any event by no later than April 1, 2024. About Waldencast Founded by Michel Brousset and Hind Sebti, Waldencast’s...

Continue reading

Form 8.3 – [CITY PUB GROUP PLC (THE) – 23 02 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree CITY PUB GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [YOUNG & CO.’S BREWERY PLC – 23 02 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree YOUNG & CO.’S BREWERY PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Playtika Holding Corp. Reports Q4 and 2023 Financial Results

Announces Capital Allocation Framework and Initiates Quarterly Dividend2023 Q4 Revenue Increased 1.1% YOY; DTC Platforms Revenue Increased 7.6% YOYAnnounces Pause to Strategic Alternatives Process HERZLIYA, Israel, Feb. 26, 2024 (GLOBE NEWSWIRE) — Playtika Holding Corp. (NASDAQ: PLTK) today released financial results for its fourth quarter and fiscal year ended December 31, 2023. Capital Allocation Framework:Initiating a quarterly dividend of $0.10 per share, with future dividends subject to market conditions and Board approval. Intention to deploy $600 million to $1.2 billion of capital for M&A over the next three years. Exploring other opportunities to enhance shareholder return, including a share repurchase program in the future.Fourth Quarter 2023 Financial Highlights:Revenue of $637.9 million increased 1.2% sequentially...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.